Satellos Bioscience Inc.

MSLE ·Healthcare, Drug Manufacturers - General
Financial Statements › Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024
Operating Activities
Net Income $-24.9M $-20.6M
Depreciation & Amortization — —
Depreciation — —
Amortization — —
Stock-Based Compensation — —
Net Cash from Operating Activities $-23.6M $-18.3M
Investing Activities
Capital Expenditures $6.0K $4.0K
Business Acquisitions — —
Net Cash from Investing Activities $-9.4M $4.7M
Financing Activities
Dividends Paid — —
Stock Repurchases — —
Net Cash from Financing Activities $2.2M $37.6M
Net Change in Cash $-30.3M $23.4M
Free Cash Flow $-23.6M $-18.3M